Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy.

Journal of Zhejiang University. Science. B - 1 Dec 2005

Liu Ke-zhou, Hou Wei, Zumbika Edward, Ni Qin

Abstract excerpt

OBJECTIVE: To study the clinical features of chronic hepatitis B (CHB) patients with tyrosine-methionine-aspartate-aspartate (YMDD) mutation after lamivudine therapy. METHODS: This investigation was a retrospective study of 63 CHB patients with YMDD mutation during lamivudine therapy. Clinical data, including period and types of YMDD mutation; hepatitis B virus (HBV) DNA levels and alanine aminotransferase (ALT)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Anti-HIV Agents
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Gene Products, pol

Share to Hepatitis B, Chronic

Share to Lamivudine

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 16358376
DOI: 10.1631/jzus.2005.B1182
PMCID: PMC1390641

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy.PMID 16358376Read ↗

Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.Semantic proximity Read ↗

Interferon-α combined with lamivudine versus lamivudine monotherapy for the emergence of YMDD mutations in chronic hepatitis B infection: a meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.Semantic proximity Read ↗

The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.Semantic proximity Read ↗

Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.Semantic proximity Read ↗

[Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].Semantic proximity Read ↗

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.Semantic proximity Read ↗

The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis.Semantic proximity Read ↗

Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.Semantic proximity Read ↗

[Natural YMDD motif mutations of HBV polymerase in the chronic hepatitis B virus infected patients].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.